Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-15 (Cancelled)

16 (Previously Presented). A method for treating or suppressing host-versus-graft disease (HVGD) in a mammalian transplant recipient, comprising administering a therapeutically effective amount of an active ingredient that is a random copolymer consisting of amino acid residues selected from the group consisting of one amino acid from at least three of the following groups, the groups consisting of:

(a) lysine and arginine;

(b) glutamic acid and aspartic acid;

(c) alanine and glycine;

(d) tyrosine and tryptophan.

17 (Previously Presented). The method according to claim 16, wherein the copolymer consists of four different amino acids each from one of the groups (a) to (d).

18 (Currently Amended). The method according to claim 17, wherein the copolymer consists of a combination of alanine, glutamic acid, lysine, and tyrosine, of net overall positive electrical charge and of a molecular weight of ~~about~~ 2,000 to ~~about~~ 40,000 daltons.

19 (Currently Amended). The method according to claim 18, wherein the copolymer has a molecular weight of ~~about~~ 2,000 to ~~about~~ 13,000 daltons.

20 (Currently Amended). The method according to claim 19, wherein the copolymer is Copolymer 1 of average molecular weight of ~~about~~ 4,700 to ~~about~~ 13,000 daltons.

21 (Previously Presented). The method according to claim 16, wherein the copolymer consists of three different amino acids each from one of three groups of the groups (a) to (d), herein referred to as a terpolymer.

22 (Previously Presented). The method according to claim 21, wherein the random terpolymer consists of the amino acids tyrosine, alanine and lysine.

23 (Currently Amended). The method according to claim 22, wherein the terpolymer consists of tyrosine, alanine and lysine, in the molar ratio of from ~~about~~ 0.005 to ~~about~~ 0.25 tyrosine, from ~~about~~ 0.3 to ~~about~~ 0.6 alanine, and from ~~about~~ 0.1 to ~~about~~ 0.5 lysine, herein designated YAK.

24 (Previously Presented). The method according to claim 21, wherein the random terpolymer consists of the amino acids glutamic acid, tyrosine, and lysine.

25 (Currently Amended). The method according to claim 24, wherein the random terpolymer consists of the amino acids glutamic acid, tyrosine, and lysine in the molar ratio

of from ~~about~~ 0.005 to ~~about~~ 0.300 glutamic acid, from ~~about~~ 0.005 to ~~about~~ 0.250 tyrosine, and from ~~about~~ 0.3 to ~~about~~ 0.7 lysine, herein designated YEK.

26 (Previously Presented). The method according to claim 21, wherein the random terpolymer consists of the amino acids tyrosine, glutamic acid, and alanine.

27 (Currently Amended). The method according to claim 26, wherein the random terpolymer consists of the amino acids tyrosine, glutamic acid, and alanine in the molar ratio of from ~~about~~ 0.005 to ~~about~~ 0.25 tyrosine, from ~~about~~ 0.005 to ~~about~~ 0.3 glutamic acid, and from ~~about~~ 0.005 to ~~about~~ 0.8 alanine, herein designated YEA.

28 (Previously Presented). The method according to claim 21, wherein the random terpolymer consists of the amino acids glutamic acid, alanine and lysine.

29 (Currently Amended). The method according to claim 28, wherein the random terpolymer consists of the amino acids glutamic acid, alanine and lysine in the molar ratio of from ~~about~~ 0.005 to ~~about~~ 0.3 glutamic acid, from ~~about~~ 0.005 to ~~about~~ 0.6 alanine, and from ~~about~~ 0.2 to ~~about~~ 0.7 lysine, herein designated KEA.

30 (Previously Presented). The method according to any one of claims 16 to 29, wherein the amino acids in the

copolymers are all L-, all D- or a mixture of L- and D-amino acids.

31 (Cancelled)

32 (Previously Presented). The method according to claim 16, wherein said patient receives an HLA matched or unmatched transplant.

33 (Previously Presented). The method according to claim 32, wherein said organ or tissue is any one of heart, lung, kidney, liver, bone marrow or skin.

34 (Currently Amended). The method according to claim 16, wherein the copolymer is Copolymer 1 of average molecular weight of ~~about~~ 2,000 to ~~about~~ 20,000 daltons.